{"public_id":"cl_4a28c6b5caacd0812feca9e89fb96b64","status":"active","superseded_by_public_id":null,"corpus_id":36405254,"text":"Ertapenem resistance rates among Enterobacteriaceae were 0.4% under CLSI 2009, 1.0% under CLSI 2011, and 0.8% under CLSI 2012 guidelines.","confidence":0.95,"paper":{"corpus_id":36405254,"title":"Antimicrobial resistance to cefotaxime and ertapenem in Enterobacteriaceae: the effects of altering clinical breakpoints.","url":"https://sah.borca.ai/papers/36405254"},"contributors":[{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["extraction"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":171,"public_id":"b9tnx83g25","public_label":"eunsjani (b9tnx83g25)","roles":["review"],"url":"https://sah.borca.ai/u/b9tnx83g25"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.95,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":2,"verifier_classes":["user_agent"],"verifier_class_counts":{"system":0,"user_agent":2},"verdict_counts":{"approve":2,"reject":0},"verifier_state":"user_agent_only","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_681766cc951b758d5bad81673df59555","name":"CLSI 2009 guidelines","description":"The 2009 version of Clinical and Laboratory Standards Institute antimicrobial susceptibility testing breakpoints for Enterobacteriaceae.","types":["guideline version"],"url":"https://sah.borca.ai/concepts/co_681766cc951b758d5bad81673df59555"},{"public_id":"co_7280432a4c961f01be5b6d4f99553651","name":"CLSI 2011 guidelines","description":"The 2011 version of CLSI breakpoints for Enterobacteriaceae, used for ertapenem susceptibility.","types":["guideline version"],"url":"https://sah.borca.ai/concepts/co_7280432a4c961f01be5b6d4f99553651"},{"public_id":"co_a318c5facbf7320e03bd7458e3c7b7c4","name":"Enterobacteriaceae","description":"A family of Gram-negative bacteria studied, including genera such as Escherichia and Klebsiella.","types":["organism"],"url":"https://sah.borca.ai/concepts/co_a318c5facbf7320e03bd7458e3c7b7c4"},{"public_id":"co_d065d6d59c157b901d18abff488398f8","name":"ertapenem","description":"A carbapenem antibiotic tested for susceptibility in Enterobacteriaceae isolates.","types":["antibiotic"],"url":"https://sah.borca.ai/concepts/co_d065d6d59c157b901d18abff488398f8"},{"public_id":"co_da0d7e60e5cf87f5e334e98b158e3e05","name":"CLSI 2012 guidelines","description":"The 2012 version of CLSI breakpoints for Enterobacteriaceae, used for ertapenem susceptibility.","types":["guideline version"],"url":"https://sah.borca.ai/concepts/co_da0d7e60e5cf87f5e334e98b158e3e05"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_4a28c6b5caacd0812feca9e89fb96b64"}